{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:59:24Z","timestamp":1787885964749,"version":"build-2784847793"},"reference-count":84,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Abbot Laboratories","award":["RRTI8626"],"award-info":[{"award-number":["RRTI8626"]}]},{"name":"National Research Council","award":["RRTI8626"],"award-info":[{"award-number":["RRTI8626"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Objective: This systematic review aims to evaluate the efficacy of fluvoxamine in the treatment of anxiety disorders and obsessive-compulsive disorder (OCD) by synthesizing evidence from systematic reviews and meta-analyses. Methods: We conducted a literature search in PubMed and the Cochrane Central Register of Controlled Trials, focusing on fluvoxamine\u2019s efficacy in generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder (PD), and OCD. We included systematic reviews and meta-analyses of randomized controlled trials (RCTs) comparing fluvoxamine to a placebo or other drugs. The quality of evidence from the included reviews was assessed using A Measurement Tool to Assess Systematic Reviews\u2014version 2 (AMSTAR-2). Results: The study included fourteen systematic reviews (five for OCD, three for SAD, and six for PD), covering thirty-seven RCTs (sixteen for OCD, six for SAD, and fifteen for PD), with a total of 3621 patients (1745 with OCD, 1034 with SAD, and 842 with PD). A high-quality systematic review demonstrated that fluvoxamine is superior to a placebo in improving symptoms and the response rates for OCD. Three meta-analyses comparing fluvoxamine to clomipramine in OCD found no significant differences in efficacy regarding symptom improvement. Two additional systematic reviews, both rated as high quality, confirmed the superiority of fluvoxamine in reducing symptom severity and improving the response rates in patients with SAD compared to a placebo. However, the findings for PD were inconsistent. A meta-analysis, also rated as high quality, found that while fluvoxamine showed better response rates than a placebo, the difference was not statistically significant. Conclusions: Overall, the efficacy of fluvoxamine in the treatment of OCD and SAD was demonstrated. While some reviews highlighted its potential in alleviating GAD, its impact on panic-specific outcomes remained inconsistent.<\/jats:p>","DOI":"10.3390\/ph18030353","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T04:10:42Z","timestamp":1740975042000},"page":"353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Efficacy of Fluvoxamine in Anxiety Disorders and Obsessive-Compulsive Disorder: An Overview of Systematic Reviews and Meta-Analyses"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4320-2772","authenticated-orcid":false,"given":"Michel","family":"Haddad","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Brazilian Clinical Research Institute, S\u00e3o Paulo 01404-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Henrique Junqueira","family":"Dieckmann","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brazilian Clinical Research Institute, S\u00e3o Paulo 01404-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5446-1695","authenticated-orcid":false,"given":"Thiago Wendt","family":"Viola","sequence":"additional","affiliation":[{"name":"Brain Institute of Rio Grande do Sul, School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre 90610-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Ribeiro","family":"de Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brazilian Clinical Research Institute, S\u00e3o Paulo 01404-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0155-2670","authenticated-orcid":false,"given":"Naielly Rodrigues","family":"da Silva","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brazilian Clinical Research Institute, S\u00e3o Paulo 01404-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-0112","authenticated-orcid":false,"given":"Jair de Jesus","family":"Mari","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo 04017-030, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders: DSM-5\u2122, American Psychiatric Publishing, Inc.. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-019-0102-3","article-title":"Obsessive-compulsive disorder","volume":"5","author":"Stein","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0924-9338(00)00211-X","article-title":"Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study","volume":"15","author":"Wittchen","year":"2000","journal-title":"Eur. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Koury, M.A., and Rapaport, M.H. (2007). Quality of Life Impairment in Anxiety Disorders. Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders: New Perspectives on Research and Treatment, Ritsner, M.S., Awad, A.G., Eds., Springer.","DOI":"10.1007\/978-1-4020-5779-3_14"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jad.2023.08.049","article-title":"The differences of event-related potential components in patients with comorbid depression and anxiety, depression, or anxiety alone","volume":"340","author":"Zhou","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-981-32-9705-0_14","article-title":"Comorbid Anxiety and Depression: Clinical and Conceptual Consideration and Transdiagnostic Treatment","volume":"1191","author":"Choi","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sartorao, A.L., and Sartorao-Filho, C.I. (2024). Anxiety and Depression Disorders in Undergraduate Medical Students During the COVID-19 Pandemic: An Integrative Literature Review. Int. J. Environ. Res. Public. Health, 21.","DOI":"10.20944\/preprints202410.0037.v1"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1001\/jama.2022.22744","article-title":"Anxiety Disorders: A Review","volume":"328","author":"Szuhany","year":"2022","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Han, H., and Midorikawa, A. (2024). Depression Accompanied by Hopelessness Is Associated with More Negative Future Thinking. Healthcare, 12.","DOI":"10.3390\/healthcare12121208"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archpsyc.1989.01810010038006","article-title":"Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_14","unstructured":"(2001). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N. Engl. J. Med., 344, 1279\u20131285."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.biopsych.2007.04.001","article-title":"High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: A positron emission tomography study using [11C]SA4503","volume":"62","author":"Ishikawa","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hup.1106","article-title":"Cognition and depression: The effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered","volume":"25","author":"Hindmarch","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ren, P., Wang, J., Li, N., Li, G., Ma, H., Zhao, Y., and Li, Y. (2022). Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.925879"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1871524910909030197","article-title":"Sigma-1 receptors and selective serotonin reuptake inhibitors: Clinical implications of their relationship","volume":"9","author":"Hashimoto","year":"2009","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S1092852900002480","article-title":"Treatment of Obsessive-Compulsive Disorder","volume":"12","author":"Stein","year":"2007","journal-title":"CNS Spectr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","article-title":"Efficacy of treatments for anxiety disorders: A meta-analysis","volume":"30","author":"Bandelow","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_21","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2023). Chapter V: Overviews of Reviews. Cochrane Handbook for Systematic Reviews of Interventions Version 6.4, Cochrane."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_23","unstructured":"Booth, A. (2016). Evident Guidance for Reviewing the Evidence: A Compendium of Methodological Literature and Websites, University of Sheffield."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/sim.8781","article-title":"Evaluation of various estimators for standardized mean difference in meta-analysis","volume":"40","author":"Lin","year":"2021","journal-title":"Stat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1192\/bjp.166.4.424","article-title":"Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review","volume":"166","author":"Piccinelli","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archpsyc.1995.03950130053006","article-title":"Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis","volume":"52","author":"Greist","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004714-200206000-00012","article-title":"Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder","volume":"22","author":"Ackerman","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1745-7599.2009.00408.x","article-title":"Efficacy of treatments for patients with obsessive-compulsive disorder: A systematic review","volume":"21","author":"Choi","year":"2009","journal-title":"J. Am. Acad. Nurse Pract."},{"key":"ref_30","first-page":"CD001765","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","volume":"2008","author":"Soomro","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/YIC.0b013e3282f4224a","article-title":"Efficacy and tolerability of second-generation antidepressants in social anxiety disorder","volume":"23","author":"Hansen","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e11547","DOI":"10.1097\/MD.0000000000011547","article-title":"Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: A meta-analysis","volume":"97","author":"Liu","year":"2018","journal-title":"Medicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/neu.2020.6","article-title":"Pharmacological treatments for social anxiety disorder in adults: A systematic review and network meta-analysis","volume":"32","author":"Williams","year":"2020","journal-title":"Acta Neuropsychiatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004850-199503000-00006","article-title":"Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis","volume":"10","author":"Boyer","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1586\/ern.10.110","article-title":"Selective serotonin-reuptake inhibitors in the treatment of panic disorder: A systematic review of placebo-controlled studies","volume":"10","author":"Mochcovitch","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/NDT.S12979","article-title":"Antianxiety medications for the treatment of complex agoraphobia: Pharmacological interventions for a behavioral condition","volume":"7","author":"Perna","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/YIC.0b013e32835a5d2e","article-title":"Newer antidepressants and panic disorder: A meta-analysis","volume":"28","author":"Andrisano","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102664","DOI":"10.1016\/j.ajp.2021.102664","article-title":"Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: A systematic review and network meta-analysis","volume":"60","author":"Du","year":"2021","journal-title":"Asian J. Psychiatr."},{"key":"ref_39","first-page":"CD012729","article-title":"Pharmacological treatments in panic disorder in adults: A network meta-analysis","volume":"11","author":"Guaiana","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-0447.2006.00767.x","article-title":"Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder","volume":"113","author":"Aardema","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"40361","DOI":"10.4088\/PCC.21m03065","article-title":"Early Improvement as a Predictor of Treatment Response in Patients With Obsessive-Compulsive Disorder: A 12-Week Randomized Trial of Sertraline and Fluvoxamine","volume":"24","author":"Brar","year":"2022","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1176\/ajp.146.10.1328","article-title":"Obsessive-compulsive disorder: A double-blind, placebo-controlled trial of clomipramine in 27 patients","volume":"146","author":"Jenike","year":"1989","journal-title":"Am. J. Psychiatry"},{"key":"ref_43","first-page":"4","article-title":"The epidemiology and differential diagnosis of obsessive compulsive disorder","volume":"53","author":"Rasmussen","year":"1992","journal-title":"J. Clin. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10401239209150443","article-title":"Short- and long-term treatment of obsessive-compulsive disorder with fluvoxamine","volume":"4","author":"Mallya","year":"1992","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4088\/JCP.v64n0604","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder","volume":"64","author":"Hollander","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004850-199603000-00003","article-title":"Treatment of obsessive-compulsive disorder with fluvoxamine: A multicentre, double-blind, placebo-controlled trial","volume":"11","author":"Goodman","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_47","unstructured":"Greist, J.H. (1992, January 29). Fluvoxamine in OCD: A multicentre parallel design double-blind placebo controlled trial. Presented at the 18th Collegium Internationale NeuroPsychopharmacologicum Congress, Nice, France."},{"key":"ref_48","first-page":"409","article-title":"Clinical usefulness of Fluvoxamine Maleate (SME3110), a selective serotonin reuptake inhibitor, in the treatment of obsessive compulsive disorder: A double blind, placebo-controlled study investigating the therapeutic dose range and the efficacy of SME3110","volume":"12","author":"Nakajima","year":"1996","journal-title":"J. Clin. Ther. Med."},{"key":"ref_49","first-page":"63","article-title":"Fluvoxamine vs. clomipramine treatment in obsessive-compulsive disorder: A preliminary study","volume":"8","author":"Smeraldi","year":"1992","journal-title":"New Trends Exp. Clin. Psychiatry"},{"key":"ref_50","first-page":"301","article-title":"Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: A multicenter, randomized, double-blind, parallel group comparison","volume":"55","author":"Freeman","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004714-199604000-00004","article-title":"Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison","volume":"16","author":"Koran","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00004850-199705000-00002","article-title":"A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder","volume":"12","author":"Milanfranchi","year":"1997","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hup.317","article-title":"Fluvoxamine in obsessive-compulsive disorder: Similar efficacy but superior tolerability in comparison with clomipramine","volume":"16","author":"Mundo","year":"2001","journal-title":"Hum. Psychopharmacol."},{"key":"ref_54","first-page":"279","article-title":"Results of a double blind placebo controlled trial of a new serotoin reuptake inhibitor, sertraline, in the treatment of obsessive compulsive disorder","volume":"26","author":"Goodman","year":"1990","journal-title":"Psychopharmacol. Bull."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/01.jcp.0000106222.36344.96","article-title":"Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder","volume":"24","author":"Davidson","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S1461145706006602","article-title":"Fluvoxamine treatment of generalized social anxiety disorder in Japan: A randomized double-blind, placebo-controlled study","volume":"10","author":"Asakura","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S146114570300364X","article-title":"Fluvoxamine CR in the long-term treatment of social anxiety disorder: The 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial","volume":"6","author":"Stein","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","article-title":"Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study","volume":"156","author":"Stein","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","article-title":"Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine","volume":"115","author":"Westenberg","year":"1994","journal-title":"Psychopharmacology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.jcp.0000104906.75206.8b","article-title":"A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder","volume":"24","author":"Westenberg","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: A multi-center, double-blind, placebo-controlled study in outpatients","volume":"103","author":"Asnis","year":"2001","journal-title":"Psychiatry Res."},{"key":"ref_62","first-page":"135","article-title":"A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia","volume":"32","author":"Bakish","year":"1996","journal-title":"Psychopharmacol. Bull."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archpsyc.1993.01820130046008","article-title":"A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder","volume":"50","author":"Black","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1521\/pedi.1996.10.2.185","article-title":"The effect of fluvoxamine, cognitive therapy, and placebo on abnormal personality traits in 44 patients with panic disorder","volume":"10","author":"Black","year":"1996","journal-title":"J. Personal. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004850-198801000-00005","article-title":"Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline","volume":"3","author":"Westenberg","year":"1988","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02245749","article-title":"Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin","volume":"102","author":"Westenberg","year":"1990","journal-title":"Psychopharmacology"},{"key":"ref_67","first-page":"321","article-title":"Effect of fluvoxamine on panic disorder","volume":"13","author":"McLeod","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q","article-title":"Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder","volume":"2","author":"Nair","year":"1996","journal-title":"Anxiety"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00004714-200106000-00014","article-title":"Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder","volume":"21","author":"Palatnik","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00004714-200206000-00011","article-title":"Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome","volume":"22","author":"Perna","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4088\/JCP.v57n1107","article-title":"Fluvoxamine attenuates panic induced by 35% CO2 challenge","volume":"57","author":"Pols","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-2007-979311","article-title":"Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine","volume":"31","author":"Sandmann","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0887-6185(96)00008-4","article-title":"Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia","volume":"10","author":"Sharp","year":"1996","journal-title":"J. Anxiety Disord."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00004714-199608000-00005","article-title":"A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder","volume":"16","author":"Westenberg","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000284628","article-title":"Serotonin-influencing drugs in the treatment of panic disorder","volume":"22","author":"Westenberg","year":"1989","journal-title":"Psychopathology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.4088\/JCP.v69n1101","article-title":"The sigma enigma: Can sigma receptors provide a novel target for disorders of mood and cognition?","volume":"69","author":"Stahl","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Nishimura, T., Ishima, T., Iyo, M., and Hashimoto, K. (2008). Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: Role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002558"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-3-319-50174-1_10","article-title":"Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection","volume":"964","author":"Nguyen","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/0004867418799453","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder","volume":"52","author":"Andrews","year":"2018","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMcp1614701","article-title":"Social Anxiety Disorder","volume":"376","author":"Leichsenring","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Katzman, M.A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., Antony, M.M., Bouchard, S., Brunet, A., and Flament, M. (2014). Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry, 14.","DOI":"10.1186\/1471-244X-14-S1-S1"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1080\/14737175.2019.1666713","article-title":"Therapeutic strategies for social anxiety disorder: Where are we now?","volume":"19","author":"Pelissolo","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/npr2.12275","article-title":"Antidepressants for social anxiety disorder: A systematic review and meta-analysis","volume":"42","author":"Mitsui","year":"2022","journal-title":"Neuropsychopharmacol. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14740338.2018.1429403","article-title":"Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines","volume":"17","author":"Quagliato","year":"2018","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:45:06Z","timestamp":1760028306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":84,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ph18030353"],"URL":"https:\/\/doi.org\/10.3390\/ph18030353","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}